[Erythropoietin and intravenous iron to save blood in surgery].
Recombinant human erythropoietin (rHuEPO) and intravenous (i.v.) iron administration may be useful tools to save blood in surgery. In the perioperative period, rHuEPO should be used in slightly anemic patients for whom an autologous predonation program is not recommended (or feasible). In such cases, i.v. iron is only given if there is a functional or real iron deficiency state. In the post-operative period, i.v. iron is administered in association with rHuEPO in an attempt to rapidly correct severe post-operative anemia. The same regimen is used for patients undergoing surgery for inflammatory bowel disease and rheumatoid arthritis. Finally, other particular categories of patients, such as those with reduced body weight (< 50 kg), candidates for surgery with increased blood needs (> 5 units), or those with a too-short period of time before surgery, also benefit from the administration of these two drugs.
Beris
P
P
Département de Médecine Interne, Hôpital Cantonal, Genève. Photis.Beris@hcuge.ch
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000740:Anemia / Q000628:therapy; D001172:Arthritis, Rheumatoid / Q000601:surgery; D016063:Blood Loss, Surgical; D001804:Blood Transfusion, Autologous; D004921:Erythropoietin / Q000008:administration & dosage*; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000601:surgery; D007262:Infusions, Intravenous; D007501:Iron / Q000008:administration & dosage*; D000090463:Iron Deficiencies; D011182:Postoperative Care; D011183:Postoperative Complications / Q000628:therapy; D011300:Preoperative Care; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D012307:Risk Factors; D013514:Surgical Procedures, Operative; D013997:Time Factors
D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin; D007501:Iron